Systems Immunology of Long Covid: Insights from the STOP-PASC Clinical Trial 2265936
The Journal of Immunology · 01.08.2026 · 215 (Supplement_1)
DOI: 10.1093/jimmun/vkag141.1084 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.07.2026. Verfasst von Evan Maestri und 22 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Post Acute Sequelae of COVID-19 (PASC), also called Long COVID, is an infection-associated chronic syndrome. Despite proposed viral persistence mechanisms, no therapeutic benefit was observed in randomized placebo-controlled trials of nirmatrelvir/ritonavir (NMV/r) in adults with Long COVID, including the Selective Trial of Paxlovid for PASC (STOP-PASC). This systems immunology analysis aimed to characterize immune profiles of participants during clinical trial intervention, identify biomarkers associated with patient-reported outcomes, and investigate potential mechanisms underlying Long COVID.
Methods
We performed comprehensive immunological profiling of 152 STOP-PASC trial participants using plasma proteomics (Olink® Explore HT 5400 panel), autoantigen arrays, viral serology, and microclot assays at baseline, day 15, and week 10. We assessed associations between immune features and patient-reported outcomes. We also conducted meta-analysis of nine independent Long COVID proteomics cohorts (n = 590 total samples) to identify conserved inflammatory signatures.
Results
NMV/r treatment at day 15 compared with baseline induced transient changes in plasma proteins that normalized by week 10, primarily impacting myeloid cell/monocyte, lysosome, and complement activation pathways. Cardiovascular symptoms were negatively associated with SARS-CoV-2 antibody levels at baseline. No widespread differences in autoantibody profiles, Epstein-Barr virus (EBV) reactivation, or microclotting were observed between STOP-PASC Long COVID participants, pre-pandemic controls, and individuals without Long COVID. Meta-analysis of publicly available Olink® data from Long COVID cohorts identified a conserved 60-protein Long COVID Signature (LCS) score revealing multi-compartment immune activation involving monocyte, neutrophil, and T/NK cell modules.
Conclusion
These findings advance our understanding of Long COVID immunology and may help direct future proteomic biomarker endpoints for Long COVID clinical trials. Funding Source Pfizer Topic Categories Computational and Systems Immunology (COMP)
Zitieren
APA
Maestri, E., Kwon, W. J., Zheng, H., Prestwood, T., Hedlin, H., Liang, J., McCann, H., Jones, B., Lu, R., Wiley, G., Haraguchi, E., Wirz, O., Afaghani, J., Lam, B., Wood, J., Boyd, S., Guthridge, J., Singh, U., Bonilla, H., …, & Khatri, P. (2026). Systems Immunology of Long Covid: Insights from the STOP-PASC Clinical Trial 2265936. The Journal of Immunology, 215(Supplement_1). https://doi.org/10.1093/jimmun/vkag141.1084
Vancouver
Maestri E, Kwon WJ, Zheng H, Prestwood T, Hedlin H, Liang J, et al. Systems Immunology of Long Covid: Insights from the STOP-PASC Clinical Trial 2265936. The Journal of Immunology. 2026;215(Supplement_1). doi:10.1093/jimmun/vkag141.1084
BibTeX
@article{Maestri2026,
author = {Maestri, Evan and Kwon, Woo Joo and Zheng, Hong and Prestwood, Tyler and Hedlin, Haley and Liang, Jane and McCann, Holly and Jones, Ben and Lu, Rufei and Wiley, Graham and Haraguchi, Emily and Wirz, Oliver and Afaghani, Jumana and Lam, Brandon and Wood, Jeremy and Boyd, Scott and Guthridge, Joel and Singh, Upinder and Bonilla, Hector and Jagannathan, Prasanna and Utz, P J and Geng, Linda and Khatri, Purvesh},
title = {Systems Immunology of Long Covid: Insights from the STOP-PASC Clinical Trial 2265936},
journal = {The Journal of Immunology},
year = {2026},
volume = {215},
number = {Supplement_1},
doi = {10.1093/jimmun/vkag141.1084}
}
EUVIMED